Drug Trial Radar · NCT06488313
A Study to Evaluate the Pharmacodynamics and Safety of ARCT-810 in Participants With OTCD
Last checked: Nov 19, 2026Latest source record: Mar 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
9
Planned (sponsor's estimate)
Start
Nov 4, 2024
Primary completion
Jun 1, 2026
Study completion Sep 1, 2026
Sponsor
- Lead sponsor
- Arcturus Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 5, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Evaluate the safety and pharmacodynamics of multiple doses of ARCT-810 in adolescent and adult participants with OTC deficiency.
Conditions
- OTC Deficiency
- Ornithine Transcarbamylase Deficiency
- OTCD
Interventions
ARCT-810Biological
ARCT-810 is an investigational medicinal product comprising Ornithine Transcarbamylase (OTC) messenger RNA (mRNA) formulated in a lipid nanoparticle (LNP).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence, severity and dose-relationship of adverse events (AEs)Time frame: Day 85
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Uncommon Cures
Chevy Chase, Maryland · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.